In a groundbreaking move, the Trump administration has announced the reclassification of medical marijuana, shifting it to Schedule III and easing federal restrictions. This change opens the door for increased medical research into the benefits and risks of cannabis, while also paving the way for potential medical cannabis expansion in states like North Carolina and Texas. Companies in the cannabis industry are exploring opportunities for IPOs and private funding, with a mixed reaction from different states on how the new rules will affect their marijuana operations. The Department of Justice and the DEA have rolled out new regulations, impacting dispensaries and medical marijuana users nationwide. However, confusion remains among some regulators and businesses as they navigate this unexpected shift in federal cannabis policy.